Literature DB >> 25534993

Prostate cancer: Enzalutamide--differential cross resistance with taxanes.

Annette Fenner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25534993     DOI： 10.1038/nrurol.2014.353

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

Authors:  Robert J van Soest; Ellen S de Morrée; Charlotte F Kweldam; Corrina M A de Ridder; Erik A C Wiemer; Ron H J Mathijssen; Ronald de Wit; Wytske M van Weerden
Journal:  Eur Urol       Date:  2014-12-04       Impact factor: 20.096
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.